Free Trial

Windtree Therapeutics (WINT) Competitors

Windtree Therapeutics logo
$0.52 -0.02 (-3.58%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$0.52 +0.00 (+0.08%)
As of 08/14/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

WINT vs. CHRO, ADXN, CLRB, CYCN, SNPX, TAOX, BTAI, TLPH, KZIA, and BMRA

Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Chromocell Therapeutics (CHRO), Addex Therapeutics (ADXN), Cellectar Biosciences (CLRB), Cyclerion Therapeutics (CYCN), Synaptogenix (SNPX), Synaptogenix (TAOX), BioXcel Therapeutics (BTAI), Talphera (TLPH), Novogen (KZIA), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry.

Windtree Therapeutics vs. Its Competitors

Chromocell Therapeutics (NYSE:CHRO) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Chromocell Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chromocell TherapeuticsN/AN/A-$7.38M-$1.24-1.08
Windtree TherapeuticsN/AN/A-$1.79M-$823.470.00

Windtree Therapeutics has a consensus target price of $350.00, suggesting a potential upside of 67,650.68%. Given Windtree Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Windtree Therapeutics is more favorable than Chromocell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromocell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Windtree Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Chromocell Therapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Chromocell TherapeuticsN/A N/A -453.90%
Windtree Therapeutics N/A -227.93%-56.46%

78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by insiders. Comparatively, 0.3% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Windtree Therapeutics had 5 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 5 mentions for Windtree Therapeutics and 0 mentions for Chromocell Therapeutics. Windtree Therapeutics' average media sentiment score of 0.80 beat Chromocell Therapeutics' score of 0.00 indicating that Windtree Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Chromocell Therapeutics Neutral
Windtree Therapeutics Positive

Chromocell Therapeutics has a beta of 3.63, indicating that its stock price is 263% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.

Summary

Windtree Therapeutics beats Chromocell Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Windtree Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WINT vs. The Competition

MetricWindtree TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.96M$3.10B$5.61B$9.84B
Dividend YieldN/A2.23%4.61%4.07%
P/E Ratio0.0020.4930.2925.74
Price / SalesN/A356.37463.41115.83
Price / CashN/A43.0338.2159.48
Price / Book0.018.608.826.15
Net Income-$1.79M-$54.65M$3.25B$265.06M
7 Day Performance-5.59%5.86%3.70%2.60%
1 Month Performance-37.65%8.86%5.84%2.83%
1 Year Performance-99.91%13.33%29.92%25.58%

Windtree Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WINT
Windtree Therapeutics
2.8772 of 5 stars
$0.52
-3.6%
$350.00
+67,650.7%
-99.9%$1.96MN/A0.0030Upcoming Earnings
Short Interest ↓
Gap Down
CHRO
Chromocell Therapeutics
N/A$1.34
+6.3%
N/A-83.0%$8.69MN/A-1.084Gap Up
High Trading Volume
ADXN
Addex Therapeutics
2.7389 of 5 stars
$8.24
+1.7%
$30.00
+264.3%
+3.0%$8.58M$460K-24.2230
CLRB
Cellectar Biosciences
2.7663 of 5 stars
$5.06
+7.2%
$375.00
+7,311.1%
-92.6%$8.54MN/A-0.2310News Coverage
Analyst Forecast
Short Interest ↑
CYCN
Cyclerion Therapeutics
2.7174 of 5 stars
$2.79
+7.5%
N/A-26.3%$8.33M$2M-2.4030Short Interest ↓
SNPX
Synaptogenix
N/A$5.99
-5.4%
N/A+156.3%$8.33MN/A-0.594
TAOX
Synaptogenix
N/A$6.49
+8.3%
N/AN/A$8.32MN/A-0.644Positive News
Gap Down
BTAI
BioXcel Therapeutics
4.4611 of 5 stars
$2.54
+85.4%
$42.60
+1,577.2%
-56.3%$8.30M$2.27M-0.1990Earnings Report
Short Interest ↓
Gap Down
High Trading Volume
TLPH
Talphera
3.3844 of 5 stars
$0.40
+0.1%
$5.00
+1,140.7%
-50.0%$8.25M$650K-0.9019News Coverage
Negative News
Earnings Report
Short Interest ↓
Gap Up
KZIA
Novogen
3.9843 of 5 stars
$8.34
+2.0%
$14.00
+67.9%
-53.7%$8.24M$1.51M0.0012Short Interest ↓
Gap Down
BMRA
Biomerica
1.1633 of 5 stars
$3.15
-2.5%
N/A+43.9%$8.23M$5.41M-1.3660News Coverage
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:WINT) was last updated on 8/15/2025 by MarketBeat.com Staff
From Our Partners